Melatonin shows little effect on glycemic control in type 2 diabetes
This study investigated the effect of melatonin on glycemic control in patients with type 2 diabetes, finding no significant differences between melatonin and placebo groups.
Research feed
Recently added diabetes research, organized by intervention and outcome.
Sorted by when Dediabetes added each study.
This study investigated the effect of melatonin on glycemic control in patients with type 2 diabetes, finding no significant differences between melatonin and placebo groups.
This study investigated the effects of melatonin supplementation on glycemic control in patients with type 2 diabetes and chronic periodontitis, finding significant improvements in various health markers.
Curcumin supplementation significantly improved glycemic control and reduced inflammation in patients with metabolic dysfunction-associated steatotic liver disease.
This study evaluated the effectiveness of tirzepatide in resolving metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis.
This study compared the effects of Saroglitazar and Pioglitazone on liver health and blood sugar control in patients with Type 2 Diabetes and liver disease, finding significant improvements in certain measures.
This study investigated the effects of a multispecies probiotic supplement combined with non-surgical periodontal therapy in patients with type 2 diabetes, finding significant improvements in inflammatory and periodontal markers.
This study investigated the effects of periodontal treatment on the risk of cerebral infarction in patients with type 2 diabetes mellitus, finding significant reductions in inflammatory markers.
Cyclic yoga significantly improved metabolic health markers in women with type 2 diabetes and non-alcoholic fatty liver disease compared to a control group.
This study examined the effects of a dietary supplement containing cinnamon, chromium, and carnosine on fasting plasma glucose in prediabetic individuals, finding a significant reduction in fasting plasma glucose levels compared to placebo.
This study evaluated the efficacy and safety of HD-6277, a GPR40 agonist, in adults with Type 2 diabetes, finding significant reductions in HbA1c and fasting plasma glucose.
Latest Evidence
Build your workspace to keep track of the latest diabetes research.